Table 7.

Univariate and multivariate Cox regression analysis to determine predictors of disease recurrence or death within this series.

DFS							OS
Parameter	HR	95% CI	P-value	OR	95% CI	P-value	HR	95% CI	p-value	OR	95% CI	P-value
	Univariable			Multivariable			Univariable			Multivariable
Age >65	2.336	1.485–3.676	<0.001∗				3.343	2.101–5.319	<0.001∗	2.069	1.186–3.611	0.010∗
Symptomatic	19.087	2.656–137.208	0.003∗	13.345	1.836–97.008	0.010∗	14.727	2.044–106.118	0.008∗	8.541	1.163–62.730	0.035∗
IDC	0.577	0.337 - 0.987	0.045∗				0.537	0.307 - 1.937	0.029∗
Tumour >50 mm	2.001	0.997–4.015	0.051				2.029	1.001–4.109	0.049∗
Grade 3	1.241	0.786–1.958	0.354				0.995	0.621–1.594	0.982
N2/N3	2.671	1.603–4.450	<0.001∗	2.570	1.533–4.309	<0.001∗	2.357	1.374–4.042	0.002∗	2.065	1.156–3.688	0.014∗
ER negative	1.319	0.847–2.054	0.221				1.604	1.006–2.557	0.047∗
PgR negative	1.631	1.030–2.583	0.037∗	1.878	1.125–3.134	0.016∗	1.968	1.192–3.251	0.008∗
HER2 enriched	1.482	0.949–2.314	0.083				1.796	1.126–2.866	0.014∗
pCR Breast	0.470	0.222–0.994	0.048∗				0.383	0.158–0.924	0.033∗
T downstage	0.715	0.318–1.604	0.415				0.904	0.321–2.542	0.848
pCR Axilla	0.449	0.219–0.921	0.029∗				0.307	0.130–0.729	0.007∗	0.326	0.115–0.929	0.036∗
Axilla downstage	0.622	0.243–1.591	0.322				0.228	0.052–1.006	0.051

DFS; disease-free survival, OS; overall survival, HR; hazards ratio, 95% CI; 95% confidence interval, IDC; invasive ductal carcinoma, N2; nodal stage 2, ER; estrogen receptor, PgR; progesterone receptor, HER2; human epidermal growth factor receptor-2 molecular subtype, T; tumour, pCR; pathological complete response.

∗denotes statistical significance.